Ludwig Boltzmann Gesellschaft, Cluster Translational Oncology, Vienna, Austria Similar to p73, the tumor suppressor gene p53 is subject to alternative splicing. Besides p53DE6 and p53b, we identified p53f, p53d and p53e, arising from alternative splicing of exon 6 and intron 9, respectively. p53 splice variants were present in 18 of 34 ovarian cancer cell lines (52.9%) and 134 of 245 primary ovarian cancers (54.7%). p53d expression was associated with impaired response to primary platinum-based chemotherapy (P ¼ 0.032). Also, p53d expression constituted an independent prognostic marker for recurrence-free and overall survival (hazard ratio 1.854, 95% confidence interval 1.121-3.065, P ¼ 0.016; and hazard ratio 1.937, 95% confidence interval 1.177-3.186, P ¼ 0.009, respectively). p53b expression was associated with adverse clinicopathologic markers, that is, serous and poorly differentiated cancers (P ¼ 0.002 and P ¼ 0.008, respectively), and correlated with worse recurrence-free survival in patients exhibiting functionally active p53 (P ¼ 0.049). DN 0 p73 constituted the main N-terminally truncated p73 isoform and was preferentially found in ovarian cancer cell lines showing functionally active p53, supporting our hypothesis that N-terminally truncated p73 isoforms can alleviate the selection pressure for p53 mutations by the inhibition of p53 protein function.
Similar to p73, the tumor suppressor gene p53 is subject to alternative splicing. Besides p53DE6 and p53b, we identified p53f, p53d and p53e, arising from alternative splicing of exon 6 and intron 9, respectively. p53 splice variants were present in 18 of 34 ovarian cancer cell lines (52.9%) and 134 of 245 primary ovarian cancers (54.7%). p53d expression was associated with impaired response to primary platinum-based chemotherapy (P ¼ 0.032). Also, p53d expression constituted an independent prognostic marker for recurrence-free and overall survival (hazard ratio 1.854, 95% confidence interval 1.121-3.065, P ¼ 0.016; and hazard ratio 1.937, 95% confidence interval 1.177-3.186, P ¼ 0.009, respectively). p53b expression was associated with adverse clinicopathologic markers, that is, serous and poorly differentiated cancers (P ¼ 0.002 and P ¼ 0.008, respectively), and correlated with worse recurrence-free survival in patients exhibiting functionally active p53 (P ¼ 0.049). DN 0 p73 constituted the main N-terminally truncated p73 isoform and was preferentially found in ovarian cancer cell lines showing functionally active p53, supporting our hypothesis that N-terminally truncated p73 isoforms can alleviate the selection pressure for p53 mutations by the inhibition of p53 protein function. Oncogene (2010) 29, 1997-2004; doi:10.1038/onc.2009.482 ; published online 18 January 2010 Keywords: ovarian cancer; p53; p73; splice variants Many cancer-associated genes, including the tumor suppressor p53, exhibit alternative pre-mRNA splicing. This produces various p53 splice variants with partially unknown function that add further complexity to the role of p53 in cancer. Alternative spicing at the C terminus gives rise to p53b, containing 133 additional bp from intron 9 (exon 9b), and p53g, retaining the distal 58 bp of exon 9b ( Figure 1a ). Consequently, these insertions result in a frameshift and introduce a premature termination codon. Instead of the basic regulatory domain and most of the oligomerization domain (OD), the p53b and p53g proteins possess unique shortened C-terminal tails of 10 and 15 new residues, respectively. Another splice variant, p53DE6, is devoid of exon 6 and encodes a C-terminally truncated p53 protein that misses part of the DNA binding domain and the entire OD (Jolly et al., 1994) .
Splice site mutations constitute the most common cause for alternative splicing. To date, 29 different p53 splice site mutations have been described in various types of cancers (Holmila et al., 2003) . These mutations can result in the use of the next available legitimate splice sites, which leads to exon skipping. For example, in the splice variant p53DE6, the splice acceptor site of intron 6 is mutated (Jolly et al., 1994; Magnusson et al., 2000) . In addition, intronic mutations can create new splice sites. In p53b, an 8 bp deletion within intron 9 results in a novel splice donor site (Chow et al., 1993) . Alternative splicing has also been reported in the absence of concomitant mutations (Bourdon et al., 2005) .
The function of C-terminally truncated p53 splice variants has not been fully disclosed and studies examining their expression patterns in human cancers are rare (for review see Ja¨nicke et al., 2009) . While p53b was present in 8 normal breast tissues, it was only detected in 10 of 30 breast cancers (Bourdon et al., 2005) . In contrast, p53b showed very low expression in normal melanocytes, but was expressed in 15 of 16 melanoma cell lines (Avery-Kiejda et al., 2008) . In squamous carcinomas of the head and neck and adjacent tissues as well as oral lichen planus, a chronic inflammatory, premalignant condition, p53b was the most abundant p53 splice variant (Boldrup et al., 2007 , Ebrahimi et al., 2008 . Due to the small numbers of cases, the clinical relevance of p53b has not been evaluated. The aberrant expression of p53b in cancers suggests a possible role in tumorigenesis.
Similarly, p73, another member of the p53 gene family, gives rise to various isoforms. Aside from the full-length proapoptotic TAp73, the N-terminally truncated isoform DN 0 p73 is generated from the P1 promoter by alternative splicing. DNp73 is produced by the alternative promoter P2 in intron 3 (Figure 1b) . DN 0 p73 and DNp73 encode the same protein product that lacks the transactivation domain and thus fails to induce cell-cycle arrest and apoptosis. As it retains the DNA binding domain and OD, it acts as powerful dominant-negative inhibitor of both TAp73 and wildtype p53. In distinct cancer types, N-terminally truncated p73 isoforms constitute an independent adverse marker for survival (for review see Oswald and Stiewe, 2008) . For ovarian cancer, we have previously shown a prognostic significance of DN 0 p73 expression (Concin et al., 2005) .
Using the yeast-based assay FASAY, we determined the functional p53 status in 30 primary cultured and 4 commercially available ovarian cancer cell lines, and examined the expression of p53 splice variants and p73 isoforms using RT-PCR. To further evaluate the biological relevance of the p53 splice variants, we analyzed their expression in 245 primary ovarian cancers. Petitjean et al., 2007) . This might reflect, at least in part, the lower sensitivity of conventional methods used to determine the p53 mutational status, such as direct sequencing and immunohistochemistry, which in addition lacks specificity (Duddy et al., 2000) . The FASAY tests the critical biochemical function of p53, that is the ability to activate transcription (Flaman et al., 1995) . Sequencing of red yeast colonies, indicating functionally inactive p53, revealed the presence of inactivating p53 mutations in 11 of 25 cell lines (44%): 5 missense, 4 frameshift (3 deletions, 1 insertion) and 2 nonsense mutations ( Table 1) . Four of these cell lines additionally expressed p53 splice variants (Figure 2 ). In comparison, in the IARC TP53 Mutation Database, 25 of 31 ovarian cancer cell lines (81%) showed p53 point mutations, whereas 5 (16%) harbored frameshift and one a nonsense mutation. The mutations detected in the commercially available ovarian cancer cell lines, CAOV-3 and ES-2, are in accordance with the literature (Yaginuma and Westphal, 1992; Concin et al., 2003) . The mutation 14486C4T in OV-22 was also verified by sequencing genomic DNA and found to be heterozygous. However, the FASAY resulted in red colonies only, indicating impaired p53 function. 14 of 25 ovarian cancer cell lines (56%) exhibiting functionally inactive p53 did not show p53 mutations. In these cell lines, we found five different p53 mRNA splice variants (Table 2) . We limited our search for p53 splice variants to the C terminus, as the p53 expression vector used in the FASAY is linearized at codons 67 and 346. Thus, p53 transcripts altered at the N terminus do not fail to activate transcription of the reporter gene. In addition, the expression of the N-terminally truncated splice variants D40p53 and D133p53 has not correlated with clinicopathologic parameters and prognosis in 169 ovarian cancers (Marabese et al., 2008) .
Besides p53DE6 and p53b, we identified three novel p53 splice variants, that is p53z, p53d and p53e. However, we did not detect the previously described mutations in p53DE6 and p53b in the ovarian cancer cell lines and primary ovarian cancers despite sequencing of the entire adjacent introns (Jolly et al., 1994; Magnusson et al., 2000) . Alternative splicing in the absence of genomic mutations may be caused by alterations of regulatory factors such as heterogeneous nuclear ribonucleoparticles and SR proteins. In ovarian cancers, a marked induction and increased phosphorylation of the classical splicing factors has previously been described (Fischer et al., 2004) .
The novel p53 splice variants were caused by splice site mutations. An intronic point mutation at the splice donor site of intron 6 activates an alternative 3 0 splice site 5 bp downstream and thus gives rise to p53z ( Figures  3a and b) . The point mutation IVS9-2A4G destroys the splice acceptor site of intron 9, resulting in p53d and Alternative splicing of p53 and p73 G Hofstetter et al p53e (Figures 3c and d) . p53d contains exon 9c, consisting of 44 bp directly upstream from exon 10. It is predicted to encode a protein consisting of the same truncated OD as p53b, followed by 27 new residues (VLCIYLLLPLLCCCGSVGVSASRCSES). In cell lines, p53d was the most abundant among p53 splice variants indicating that it probably confers a growth advantage (Figure 4 ). p53e contains exon 9d, a fusion of exons 9b and 9c. Because exon 9b harbors a premature termination codon at residue 332, p53e and p53b encode the same C-terminally truncated protein. p53e and p53b were found at the same frequency in the ovarian cancer cell lines. In concordance with studies in breast cancers and melanomas, we did not detect p53g in ovarian cancer cell lines and primary ovarian cancers (Bourdon et al., 2005; Avery-Kiejda et al., 2008) . To further evaluate the biological relevance of p53 splice variants, we determined their expression in 245 primary ovarian cancers. Using the FASAY, 68 cancers (27.8%) showed functionally active p53 and 177 (72.2%) functionally inactive p53. Of these, 128 (72.3%) harbored missense, 30 (17%) frameshift, 11 (6.2%) nonsense and 8 (4.5%) only splice variants. The frequency of p53 splice variants is in accordance with 2% reported in the literature (Holmila et al., 2003) . Of 245 ovarian cancers, 134 (54.7%) possessed p53 splice variants and their expression correlated with the functional p53 status (P ¼ 0.040). In comparison to the cell lines, ovarian cancers expressed p53 splice variants at a lower level. This might be caused by an impaired nonsense-mediated mRNA decay in the cell lines, which is involved in the regulation of p53b (Anczuko´w et al., 2008) . The expression of the novel p53 splice variant p53d correlated with impaired recurrence-free and overall survival in univariate (Figure 5a and b) and multivariate analyses (hazard ratio 1.854, 95% confidence interval 1.121-3.065, P ¼ 0.016, and hazard ratio 1.937, 95% confidence interval 1.177-3.186, P ¼ 0.009, respectively). Also, cancers expressing p53d showed an increased occurrence of primary progressions during first-line chemotherapy and early recurrences within 6 months after termination of chemotherapy in comparison to cancers without p53d expression (15 of 31, 48.4% versus 45 of 165, 27.3%; Fisher's exact test, P ¼ 0.032). p53d expression did not correlate with the postoperative residual tumor, the main determinant of the success of primary cytoreductive surgery in ovarian cancer. This finding argues for an association of p53d with impaired response to primary platinum-based chemotherapy. To further evaluate the importance of p53d for the response to cytotoxic treatment, we analyzed the role of p53d in the subgroup of patients with a postoperative residual tumor (excluding 133 patients with complete macroscopic tumor removal). Among them, p53d expression was associated with worse recurrence-free and overall survival in univariate analyses (P ¼ 0.011 and P ¼ 0.003, respectively). In patients expressing p53d, the median recurrence-free survival was 9 months (2.1-15.9) compared to 17 months (12.3-21.7) in patients without p53d expression. The median overall Alternative splicing of p53 and p73 G Hofstetter et al Figure 2 The ovarian cancer cell line OV-11 exhibited all five different p53 splice variants affecting exon 6 (a) and intron 9 (b).
(a) 1, internal standard 100 bp; 2, p53DE6; 3, wild-type p53; 4, p53z (E6b); 5, internal standard 300 bp. (b) 1, internal standard 100 bp; 2, wild-type p53; 3, p53d (E9c); 4, p53b (E9b); 5, p53e (E9b þ E9c); 6, standard 300 bp. Ovarian cancer cell lines were derived from primary culture of ovarian carcinomas (Mobus et al., 1992) or purchased from the American Type Culture Collection (CAOV-3, ES-2) and the European Collection of Cell Cultures (A2780, A2780ADR). p53 splice variant expression was determined in cDNA samples prepared from polyA-RNA for the functional yeast-based assay FASAY using the primers shown in Supplementary Table 2 . The PCR products were separated on an 8% ReproGel High Resolution polyacrylamide gel using an automated laser fluorescent sequencer apparatus (ALF express DNA Sequencer; GE Healthcare Biosciences AB, Uppsala, Sweden). The Fragment Manager Software was used for size determination of the different PCR products corresponding to p53 variants. Expression intensities were derived from the peak areas obtained by gel electrophoresis with 100% being the sum of the full-length form and all variants of the respective form.
Alternative splicing of p53 and p73 G Hofstetter et al survival was 18 months (10.2-25.8) in patients with p53d expression, whereas it was 44 months (38.5-49.5) in patients without p53d expression. 11 of 17 patients (64.7%) with p53d expression showed primary progression or early recurrence, whereas this was the case in 34 of 90 patients (37.8%) without p53d expression (Fisher's exact test, P ¼ 0.059). p53b, the most abundant p53 splice variant, was found in 97 of 245 ovarian cancers (39.6%). p53b expression was associated with adverse clinicopathologic parameters, that is, serous and poorly differentiated cancers (P ¼ 0.002 and P ¼ 0.008, respectively). In patients exhibiting functionally active p53, p53b expression correlated with worse recurrence-free survival (P ¼ 0.049) and a trend for worse overall survival compared to patients without p53b expression in univariate analyses (P ¼ 0.071, Figures 5c and d) .
Interestingly, p53d and p53b, encoding proteins that are identical except for their C-terminal tail, differed in their clinical relevance in ovarian cancers. A previous study has hinted that the structure of this C-terminal tail might be of importance. While p53b was predominantly found in the nucleus, p53g was present in the nucleus and cytoplasma. Also, only p53b and not p53g was phosphorylated after irradiation . The function of p53b is still unclear and existing studies are conflicting. Initially, it has been suggested that p53b and wild-type p53 are able to form mixed complexes (Bourdon et al., 2005) . But this finding has not been confirmed using co-immunoprecipitation and EMSA supershift analyses . As p53b misses most of the OD, the structure of these mixed Figure 4 The percentage of the different p53 splice variants in the ovarian cancer cell lines exhibiting functionally inactive p53. Splice variants affecting intron 9 are depicted on top, variants affecting exon 6 at the bottom. The right column explains the color distribution.
Alternative splicing of p53 and p73 G Hofstetter et al complexes remains unclear. Also, p53b has been reported to bind the Bax and p21 promoters, but not the MDM2 promoter (Bourdon et al., 2005) . p53b lacked intrinsic transcriptional activity and enhanced wild-type p53 activity at the Bax, but not the p21 promoter, upon stress (Bourdon et al., 2005) . Another study has reported that p53b increases wild-type p53 activity at the p21 and Puma promoter (Avery-Kiejda et al., 2008) . Recently, it has been described that p53b is unable to bind DNA-recognition sequences and does not influence wild-type p53 transcriptional activity in luciferase reporter gene assays using different p53-responsive elements including the Bax promoter sequence . p53b might indirectly influence the function of wild-type p53 by competing for regulatory proteins that bind p53 at other sites than the OD and basic regulatory domain, such as the ASPP family. And, it is possible that p53b exhibits autonomous activities independent from wild-type p53.
p53e, p53DE6 and p53z were present in subgroups of 6, 27 and 8 primary ovarian cancers, respectively. p53z showed the highest relative expression and comprised 74.3, 31.3, 29.3 and 15 .5%, respectively, of all p53 isoforms in 4 cancers.
Next, we analyzed the expression of p73 isoforms in our collection of ovarian cancer cell lines. Although TAp73 was found in all 34 cell lines and 31 (91%) also expressed DN 0 p73, DNp73 was detected in only 2 (6%). The expression of TAp73, a proapoptotic isoform with potential tumor suppressor function, appears to be paradoxical in cancer cells. This phenomenon might be explained by the correlation between TAp73 and DN 0 p73 expression levels observed in the cell lines (Spearman correlation coefficient r ¼ 0.554, P ¼ 0.001). N-terminally truncated p73 protein has the ability to inhibit TAp73 function in vivo. Two mechanisms of inhibition have been described: direct promoter competition with N-terminally truncated p73 displacing TAp73 from its Alternative splicing of p53 and p73 G Hofstetter et al DNA binding site as well as mixed-complex formation. Of note, the presence of a single N-terminally truncated subunit within a tetramer is sufficient to abolish the transcriptional activity (Chan et al., 2004) . Also, the known higher stability of N-terminally truncated p73 protein compared to TAp73 can possibly lead to its higher intracellular concentrations even in the presence of equal mRNA levels . We therefore hypothesize that TAp73 expression might be a concomitant 'side-product' of the P1 promoter deregulation found in ovarian cancer, which is functionally abrogated by DN 0 p73. In addition, TAp73 can be inactivated by complex formation with specific p53 mutants (for review see Oswald and Stiewe, 2008) .
In our previously published series of ovarian cancer tissues, we also found DN 0 p73 overexpression in 95% of carcinomas, whereas DNp73, generated from the alternative P2 promoter, was upregulated only in a small subgroup (Concin et al., 2004) . Thus, our data collectively indicate that the P1 rather than the P2 promoter is primarily deregulated in ovarian cancer. The main N-terminally truncated p73 isoform seems to vary among distinct tumor entities. In accordance with our data in ovarian cancer, increased DN 0 p73 expression has also been reported in hepatocellular and esophageal carcinomas, whereas the P2 promoter transcript DNp73 has been found predominantly in prostate cancer (Stiewe et al., 2004; Cui et al., 2005; Guan and Chen, 2005) . One possible explanation for these differences among tumor entities might lie within the differential regulation of p73 promoter activities. E2F1 and the transcription factor early growth response 1 are direct transcriptional activators of the P1 promoter (Yu et al., 2007) . Moreover, binding sites for the transcriptional repressor ZEB have been described in a regulatory fragment located within the first intron of p73 that exerts silencer activity (Fontemaggi et al., 2001) . In neuroblastomas, the P2 promoter is at least in part regulated by epigenetic mechanisms such as methylation (Casciano et al., 2002) .
In our study, significantly higher expression levels of DN 0 p73 were found in cell lines harboring functionally active p53 in comparison to cell lines with functionally inactive p53 (P ¼ 0.04). While 6 of 9 (67%) cell lines with functional active p53 showed high DN 0 p73 expression (460th percentile), only 6 of 25 (24%) cell lines with functionally inactive p53 expressed DN 0 p73 at high levels (Supplementary Figure 1) . No difference in TAp73 expression levels was seen between these two groups (P ¼ 1.00). We reason that if N-terminally truncated p73 isoforms are oncogenic inhibitors of p53 and TAp73, their expression should preferentially occur in cancers harboring functionally active p53. Indeed, our data support the hypothesis that N-terminally truncated p73 isoforms can alleviate the selection pressure for p53 mutations by the inhibition of the p53 protein function.
In conclusion, we show that p53 splice variants are frequently expressed in primary ovarian cancers. p53 splice variants differ in their clinical relevance, implicating that they possess different functions in vivo. The novel splice variant p53d, encoding a C-terminally truncated protein, was associated with impaired response to primary platinum-based chemotherapy and constitutes an adverse prognostic marker for recurrencefree and overall survival in ovarian cancers. Although the function of p53b is still unclear, we provide first evidence for an adverse role at least in ovarian cancers exhibiting functionally active p53.
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